GlassScriptPhysician profile
Jennifer J Rodriguez
NPI 1235232752
$4,704.06
in general payments reported to CMS, 2019-2025
32 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $315 · 2021: $920 · 2022: $572 · 2023: $500 · 2024: $517 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,362.47 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $539.23 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $537.59 | 2021-2025 | Verquvo |
| Pfizer INC. | $280.68 | 2019-2025 | |
| Amgen INC. | $221.98 | 2019-2023 | Repatha |
| Astellas Pharma US INC | $172.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $157.30 | 2020-2025 | Wainua, Farxiga |
| Amarin Pharma, INC. | $138.97 | 2019-2022 | |
| Medtronic, INC. | $138.47 | 2021-2025 | Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $131.81 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $121.07 | 2019 | |
| Abbott Laboratories | $111.70 | 2021-2023 | Cardiomems |
| Regeneron Healthcare Solutions, INC. | $101.16 | 2019-2024 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.85 | 2023 | Jardiance |
| Philips North America LLC | $83.39 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $76.56 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.44 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $40.69 | 2020-2025 | Wegovy |
| Celonova Biosciences, INC. | $39.69 | 2019 | |
| W. L. Gore & Associates, INC. | $30.88 | 2024 | Gore Tag Conformable Thoracic Stent Graft |
| Bayer Healthcare Pharmaceuticals INC. | $30.25 | 2022 | |
| Alexion Pharmaceuticals, INC. | $28.13 | 2025 | Ultomiris |
| Kowa Pharmaceuticals America, INC. | $25.05 | 2019 | |
| Esperion Therapeutics, INC. | $24.85 | 2021 | |
| Motiva USA, LLC | $24.23 | 2025 | |
| Lilly USA, LLC | $24.23 | 2025 | Zepbound |
| Bard Peripheral Vascular, INC. | $21.83 | 2023 | Rotarexs 6 F X 135 Cm |
| Cardiva Medical, INC. | $20.85 | 2024 | Optowire |
| Alnylam Pharmaceuticals INC. | $19.94 | 2025 | Amvuttra |
| Medicure Pharma INC. | $13.49 | 2021 | |
| Cook Medical LLC | $12.53 | 2019 | |
| Shockwave Medical, INC | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.